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Dear Editor  
We read with interest the recent article by Larson-Casey et al., and the corresponding editorial 
by Quinton et al., published in the AJRCCM, wherein the authors demonstrate the protective 
role of macrophage Rac2 in attenuating cigarette smoke-induced pneumonia (1). We consider 
the mechanistic observations in the study are important considering that pneumonia plays a 
crucial role in inducing increased exacerbations in patients with COPD. We would like to take 
this further and suggest a wider discussion on new insights from airway wall cellularity, 
macrophage (M1/M2) phenotypic change and the role of epithelial adhesion molecules such as 
platelet activated adhesion factor (PAFR) and intercellular adhesion molecule 1 (ICAM-1) in 
this setting.  
 
Interestingly, this dysfunctionality of the immune system is evident from our previous reports 
wherein a hypo-cellular airway wall was observed in smokers and COPD patients and further, 
either no change or rather a decrease in the key immune cells such as neutrophils, CD68+ 
macrophages, and CD4+ T cells were observed when compared to non-smoker controls (2). 
The only cells that showed some significant increase were CD8+ T cells, which have also 
recently been demonstrated to be dysfunctional in clearing both bacterial and viral infections 
in COPD patients. Neutrophils seem to be in the same setting, whose ineffectiveness in 
combating bacterial infections have now been reasoned by Larson-Casey et al.  
 
We further defined macrophage populations and our findings suggests the existence of 
differential macrophage switching that occurs in airway wall compared to those in the lumen 
and alveolar macrophages (AMs) (3). In non-smokers airway wall macrophages are 
predominantly M2 (CD163+), which switch to a more M1 phenotype (CD68+ iNOS+ dual 
positive) in smokers and COPDs. In contrast , AMs switched towards a more M2 phenotype 
and was mainly driven by cytokines/chemokines that skewed towards a M2/Th2 profile (3). 
Furthermore, AMs from COPD patients had comparatively reduced iNOS expression 
compared to non-smokers, confirming dysfunctionality; a key reason for their inability to 
mount an effective response to infection and efferocytosis. We also found increases in 
Arginase-1 expression in bronchoalveolar lavage (BAL) macrophages in COPD, which is 
indicative of a shift towards an M2 phenotype (3). This is the first comprehensive human study 
so far in smokers and COPD (3). With respect to these, we are curious if Larson-Casey et al., 
have any information from their current study regarding M1/M2 macrophage populations in 
the context of Rac2 activity and effects on the clearance of pneumococci? 
The other important mechanistic approach to microbial pathogenesis is the prerequisite step of 
adherence of pathogens to the respiratory mucosa. The interaction between the epithelial and 
bacterial surface occurs through phosphorylcholine (ChoP) a molecular mimic of PAF present 
on the bacterial surface. PAFRs are expressed on the respiratory epithelium, which increases 
in response to cigarette smoke (4, 5). Both pneumococci and Haemophilus influenzae can 
attach to epithelial PAFR through ChoP and are protected partly due to dysfunctional immune 
response (4). We also observed that ICS have the potential to increase epithelial PAFR 
expression, suggesting a potential mechanism that underpins steroid dependent pneumonia (6). 
Similarly we observed an epithelial increase in the rhinovirus adhesion molecule, ICAM-1, 
suggesting involvement of more than one receptor that facilitates such mechanisms (4).  
 
Taken together, these observations suggests that macrophages seem to be the key cell 
population with potential to combat bacterial and viral infections. However, it is vital to 
understand variations in airway wall cellularity, macrophage plasticity, and epithelial 
attachment sites for both viruses and bacteria, which potentially are also upregulated in 
response to ICS treatment. We believe there is an urgent need for both further in-depth human 
and animal studies of what are the fundamental issues with COPD.  
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